CXCR7/ACKR3 Recombinant Proteins and Antibodies

CXCR7 (C-X-C chemokine receptor type 7, also known as ACKR3) is an atypical chemokine receptor that primarily binds to the chemokines CXCL12 and CXCL11. Unlike the classical receptor CXCR4, CXCR7 does not rely on G protein–mediated signaling; instead, it signals mainly through β-arrestin–dependent pathways, regulating processes such as cell migration, adhesion, survival, and angiogenesis. Recent studies have revealed that CXCR7 is highly expressed in multiple tumor types—including breast cancer, lung cancer, and glioma—as well as in cardiovascular diseases, and is associated with tumor invasion, metastasis, and drug resistance. These findings position CXCR7 as a promising and emerging therapeutic target.

In drug development, early research has focused on small-molecule antagonists and selective ligands of CXCR7, such as CCX771, which demonstrated potential in inhibiting tumor metastasis and improving cardiovascular function in animal models. Some dual CXCR4/CXCR7 inhibitors (e.g., AMD3100 derivatives) have also entered clinical investigation for hematologic malignancies and inflammatory diseases. Furthermore, as a β-arrestin–biased receptor, CXCR7 offers unique opportunities for biased ligand design, with several lead compounds under active development. With growing mechanistic insight, CXCR7 is now recognized as a potential therapeutic target not only in oncology but also in conditions such as heart failure, ischemia–reperfusion injury, and fibrosis. Overall, CXCR7, as an atypical receptor, is reshaping the traditional framework of chemokine receptor biology. Looking ahead, CXCR7-specific antagonists, dual-target inhibitors, and combination therapies with immuno-oncology agents may open new avenues for treating a variety of refractory diseases. Learn more about CXCR7 drug research >>

DIMA BIOTECH now offers a wide range of ready-to-use CXCR7-related products, including recombinant proteins, full-length membrane proteins, recombinant monoclonal antibodies, biotin/PE-labeled antibodies, and stable cell lines. In addition, we have established a B-cell seed library targeting CXCR7, enabling the rapid screening and identification of desired lead antibody molecules within 20 days. For more information, please feel free to contact us.